Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
May 2, 2024
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everybody, and thanks for joining us for Teleflex Inc.'s first quarter 2024 earnings conference call. You can find the press release and the slides that go with this call on our site, teleflex.com. Just a note that a replay is going to be posted on our website as well. If you'd like to listen to that replay, the details are in our press release from this morning. On the line with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom have prepared remarks for you, and after that we'll take your questions. Before we get started, I want to note that certain topics we'll cover on this conference call include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website; we want to caution that these statements are indeed forward looking and are subject to risks and uncertainties, and actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but are not limited to, the factors referenced in our press release today as well as our filings with the SEC, including our Form 10-K, which can be accessed on our website. Now I'll hand the call over to Liam for his remarks.
Liam Kelly
executiveThanks, Larry, and good morning, everyone. On today's call, we'll review our first-quarter results, discuss some commercial highlights, and provide an update on our 2024 financial guidance. We started 2024 on a solid note, as the momentum from last year continued into the first quarter. Teleflex revenues for the quarter were $737.8 million, reflecting a 3.8% increase year-over-year on both a GAAP and constant currency basis. Adjusted earnings per share in the first quarter came to $3.21, which is a 3.9% rise compared to the prior year. Product utilization moved in a positive direction during the quarter and remains consistent with what we anticipated. We're not counting on any sales lift from customers catching up on delayed procedures. Because Teleflex's product range is tied so heavily to critical care treatments, usage has returned to where it stood before the pandemic. Now on the subject of rising raw material costs: during Q1 we observed encouraging movement, as the decline compared with a year earlier is matching the pace we've projected for the full year. All the same, our outlook for 2024 still calls for overall inflation to run a bit above what we saw in 2023, in part due to inventory that was capitalized during 2023 and is now flowing through the income statement this year. I'd also like to provide an update on the logistics and distribution infrastructure. Our freight costs keep moving in a favorable direction. Even with the ongoing Middle East conflict, we've kept our customer service standards intact by rerouting shipments through other shipping lanes. I'd also point out that Teleflex doesn't rely on the Port of Baltimore for moving products to or from our North American distribution center. Let's now examine our first quarter revenue results more closely. First, I'll walk through the geographic segment revenues for Q1. Unless I say otherwise, every growth rate I cite is on a constant currency basis. In the Americas, revenues came in at $406.3 million, down 1.5% compared to the prior year. Those familiar with Teleflex know that last year's MSA revenues were recorded in the Americas. EMEA revenues reached $159.6 million, up 9.7% year-over-year. Most of our product families grew, with Interventional and Interventional Urology both turning in solid double-digit gains. Another boost for the region came from ET tubes, which are still recovering from last year's recall. Moving on to Asia, we brought in $84.2 million, up 11.2% from a year earlier. Growth there was spread broadly, including double-digit improvements in China, India and Southeast Asia. Let's shift now to how our global products category performed in the first quarter. As with the rest of this discussion, the global product category figures for Q1 are given on a year-over-year constant currency basis. Beginning with Vascular Access, revenue rose 2% year-over-year to $181.4 million. This quarter's performance was driven primarily by organic gains in PICCs, central access, and EZ-IO, though those gains were partially counterbalanced by the previously disclosed Endurance catheter recall. Once we pass the second quarter, the Endurance recall will no longer be a year-over-year comparison headwind, and we still anticipate chances to take share within the peripheral access market. Turning to Interventional: we posted $134.7 million in revenue, which represents 15.4% growth compared with the same period last year. Every one of our geographic segments grew, as the collection of growth drivers continues to deliver strong results. Balloon pumps, MANTA, and complex catheters were the top contributors this quarter. Shifting to Anesthesia: revenue climbed 3.2% from the prior-year period to $96.4 million, with the portfolio producing well-balanced growth. One thing worth noting: we're continuing to work through the impact of the ET tube recall that started in Q2 of 2023, and once we get through the next quarter, those revenue comparisons will no longer be a factor. Turning to Surgical, we posted $105.5 million in revenue, which represents 7.1% growth over last year even though the comparison was a tough one. The underlying momentum across our core surgical business stayed strong. Among our largest franchises, <<inaudible>>, instrumentation and our ligation portfolio were the drivers of that growth. On the Interventional Urology side, revenue was $79.7 million, up 6.1% versus the prior year. The growth there was powered by Barrigel following our October 2023 acquisition of Palette Life Sciences. As we expected, UroLift growth felt the effect of ongoing difficulties in the office side of service plus sales force training work for Barrigel during the quarter. Our guidance for full year 2024 Interventional Urology total revenue still assumes roughly 7.5% growth, and it still includes Palette revenues between $66 million and $68 million for 2024. OEM posted another strong quarter, with revenues climbing 13.6% from a year earlier to $87.7 million. Each of our 3 largest product categories saw double-digit growth in the quarter, including sustained strength in microcatheters. We also picked up a modest benefit as order timing moved out of the second quarter and into the first quarter. During Q1, revenue from other sources declined 27.1% year over year, coming in at $52.4 million. The primary driver behind this decrease compared with the prior-year period was the MSA exit by Medline that we had planned for December 2023. That concludes what I wanted to share regarding our first quarter revenue results. Moving on, I'd like to cover some commercial and clinical developments. First, an update regarding Palette Life Sciences, which stands as our most recent acquisition. It's been just over half a year since Palette Life Sciences became part of our company, and I'm pleased to report that our integration efforts are progressing right on schedule with the targets we set. Our cross-functional training for product sales continued uninterrupted during Q1, and the first stage of instruction for jewel bag representatives is set to conclude by the close of Q2. Throughout that quarter, we were busy coaching and supervising the legacy UroLift sales team on Barrigel usage, and completing the full integration of that sales force by the close of 2024 remains on schedule. Now, a few updates on products. Within Interventional Access, a limited market release got underway for the Wattson temporary pacing guidewire. Our structural heart lineup keeps expanding, and Wattson is going to complete it. At present that portfolio includes the MANTA, which is a large bore closure device, plus the Langston Dual-Lumen, used for delivering contrast and measuring pressure. Over in Surgical, we're happy to share that the Titan SGS stapler can now be purchased together with GORE SEAMGUARD Bioabsorbable staple line reinforcement material. Because this pairing addresses the clinical preferences of bariatric surgeons working in the sleeve gastrectomy space, it helps them in their work. As we look toward the remainder of 2024, our momentum on introducing new products will continue, and we have multiple launches lined up throughout our business units. Within Interventional Access, our outlook hasn't shifted when it comes to getting FDA marketing clearance and doing a limited market release for the Ringer catheter during the back half of 2024. Ringer features a distinctive balloon design that lets blood pass through a vessel even while that balloon stays inflated; our plan is to start with a PTCA indication, though once our vessel perforation trial wraps up, we'll assess chances to expand the label. Last, here's a regulatory update: back in February, we chose on our own to recall our QuickFlash radial artery and radial artery arterial line catheterization kits, following reports we received of greater resistance within the Guidewire handle and chamber while in use. This recall's financial effect was de minimis; working alongside the FDA, Teleflex also launched a voluntary field advisory notice not long ago covering Arrow FiberOptix and UltraFLEX intra-aortic balloon catheter kits. Because of reports pointing to an infrequent condition that, had it not been caught and fixed quickly, might lead to serious health consequences, such as lessened or lost hemodynamic support of the kind intra-aortic balloon pump therapy typically delivers. As of now, the FDA hasn't assigned a recall classification. Still, per the field advisory notice, customers are permitted to keep using the affected products, provided they follow the extra instructions, warnings and cautions. We anticipate the financial effect of this voluntary field action will be immaterial; that wraps up what I had prepared to say. At this point I'd like to hand the call over to Tom so he can walk through our first quarter financial results in more detail. Tom?
Tom Powell
executiveThank you, Liam, and good morning everyone. With the earlier conversation about how the company performed on revenue behind us, margins are where I'd like to start. Adjusted gross margin came in at 61.1% for the quarter, which represents a 170 basis point gain over the same period a year ago. That year-over-year improvement largely came from the favorable gross margin impact tied to ending the MSA, our purchase of Palette, and beneficial pricing resulting from cost improvement efforts, though these were partly offset by adverse movements in foreign exchange rates along with ongoing cost inflation. In the first quarter, adjusted operating margin reached 26.6%. The main factor behind the 80 basis point gain over the prior year was the pass-through effect of a stronger gross margin than twelve months ago, which was partially counterbalanced by the addition of Palette Life Science, expenses tied to operations, costs related to employees, and spending directed at expanding the business. For the first quarter, net interest expense reached $21 million, an increase from $17.5 million in the same period the previous year. This year-over-year growth in net interest expense reflects interest rates that are higher than they were a year ago, along with a bigger average debt balance taken on to fund the Palette acquisition, partially offset by more interest income. Our adjusted tax rate in the first quarter of 2024 was 13.2%, compared with 11.8% the year before. When you compare our adjusted tax rate to the prior year, the main drivers are extra expenses related to European Pillar 2 tax reform taking effect, plus discrete items that materialized during the quarter. Turning to the bottom line, first-quarter adjusted earnings per share reached $3.21, which represents a 3.9% improvement over last year. This increase in EPS year over year reflects dilution caused by the Palette Life Sciences acquisition and the additional borrowings associated with that deal. Now I'd like to discuss a few highlights regarding the balance sheet and cash flow. Operating cash flow for the first quarter was $112.8 million, compared with $84.3 million during the same period a year ago. So that $28.5 million gain came mostly from strong operating performance, plus we saw less cash going out for inventory as we trim stock levels in response to supply chains getting better. That was partly offset by receivables going up because sales were higher, and also by lower accounts payable and accrued expenses. Turning to the balance sheet: when the first quarter ended, cash came to $237.4 million, up from $222.8 million at the end of 2023. The main driver of that increase in cash on hand is cash flow from operations. Net leverage finished the quarter at about 1.7x. Even with the debt tied to buying Palette Life Sciences, we're in good financial shape, and that keeps giving us room to carry out our long-term plan for allocating capital. Now, on to financial guidance. This strong beginning to the year has us feeling good, and we're making a few targeted changes to what we expect for 2024. Our projection for 2024 constant currency revenue growth stays at 3.75% to 4.75%. If you compare that figure to the prior year, it factors in the $75.7 million in MSA revenues that disappeared, which was partially offset by extra revenue from Palette of roughly $66 million to $68 million, as Liam mentioned before. So, turning to foreign exchange. At present, we're anticipating an FX-related hit of about $12 million, and for 2024 that amounts to a 40 basis point subtraction from GAAP growth. Compare that with the figure we gave you earlier — approximately $5 million, equal to a 15 basis point headwind, for 2024. Built into this updated $12 million currency headwind is an assumed average euro exchange rate near $1.07 across 2024, while our prior outlook had relied on about $1.08. Looking at how foreign exchange is moving, our expectation for reported revenue growth in 2024 sits between 3.35% and 4.35%, equivalent to somewhere in the range of $3.074 billion to $3.104 billion. When you're building your models, keep in mind that our 2024 outlook assumes second-quarter revenues of $760 million to $765 million. That works out to year-over-year growth between 3.1% and 3.8%, and it excludes an FX headwind of roughly $6 million. We're also reaffirming that we expect 2024 gross margin to land between 60% and 60.75%. Several things are driving that gross margin guidance: the termination of the MSA, manufacturing efficiencies, price, and the Palette acquisition are all contributing positively compared with last year, while inflation and shifts in foreign currency exchange rates are partly working against them. In addition, for 2024 we still anticipate operating margin in the 26.25% to 26.75% range. The way our guidance shakes out, you're seeing gross margin flow through and restructuring give us a lift, but that's partly eaten up by adding Palette Life Sciences' operating expenses and by the money we're putting into growing the business. Now moving to the below-the-line items. For 2024, we're looking at net interest expense of roughly $78 million. The main reason our net interest expense outlook is up compared with last year is the debt we took on for the Palette acquisition, along with higher rates — though paying down debt as planned during 2024 offsets some of that. As for 2024, our expected tax rate sits near 12%; that number reflects a favorable mix, partly canceled out by discrete items from 2023 that won't show up again in 2024, and also by Pillar 2's global minimum tax. Now on earnings. We're lifting the bottom end of our guidance by $0.05, reflecting both the strong first quarter results and the revised foreign exchange headwind. As a result, our 2024 adjusted earnings per share expectation is now a range of $13.60 to $13.95. And lastly, our 2024 adjusted EPS outlook incorporates $0.87 of year-over-year headwinds stemming from incremental dilution tied to the Palette acquisition, the MSA termination, the year-over-year rise in our tax rate, mostly from the Pillar 2 minimum tax, and the updated foreign exchange headwind of $0.28. Once you adjust for those headwinds, underlying adjusted constant currency EPS growth compared with last year comes to roughly 7% at the low end of guidance and 10% at the high end. That wraps up my prepared remarks. At this point, I'd like to hand things back over to Liam, who has some final remarks.
Liam Kelly
executiveThank you, Tom. To wrap things up, I'd like to walk through our 3 main points for the first quarter of 2024. To begin, momentum carried over from the close of last year, so 2024 got off to a strong start. On the whole, both our diversified portfolio and our global business units delivered solid results. We kept operating expenses in check and stayed committed to launching new products in 2024. Once you net out the lost MSA revenues, the added palette sales and the updated foreign exchange headwind, our expectation is a headwind to 2024 growth of roughly 100 basis points versus the prior year. Next, we are in a strong position to meet the financial guidance we've set for 2024. Our attention stays squarely on carrying out this year's plan, exactly as we did in 2023. And third, our strategy of pursuing durable growth remains a priority; over time we will put money into organic growth opportunities and push innovation forward, widen our margins and carry out our disciplined approach to capital allocation so that long-term value creation is strengthened. Things are going smoothly with the Palette Life Sciences integration, and we anticipate that this acquisition will contribute meaningfully to our growth in the years ahead. That brings my prepared remarks to a close. At this point, I'd like to hand the call back to the operator so we can begin Q&A.
Patrick Wood
analystSo, starting with the first item, I'd like to understand more about OEM, which had yet another really impressive quarter. A number of separate elements are in play there. Demand conditions look quite favorable; at the same time, there's some back-and-forth competitive activity. I'm just — I want to know how you expect that to play out across the year. You brought up some phasing since certain things got pulled forward into Q1, but should we be looking for greater normalization during the back half, or growth trends similar to what we've witnessed up to now?
Liam Kelly
executivePatrick, many thanks for asking. In my view, OEM was certainly among the standout performers once more during the quarter, yet Teleflex had numerous standouts in that quarter — a genuinely powerful quarter, an excellent beginning to the year, with revenues up 3.8% and earnings climbing more quickly than revenues at 3.9%, plus lifting the low end of our earnings guidance even while absorbing some FX pressure. Turning to OEM, I do expect that phasing to occur as the year progresses, and I believe OEM is fully able to deliver double-digit growth across the whole year. There will likely be somewhat of a pullback in Q2 purely because of how the orders are phased, as you pointed out. Nevertheless, the fundamental growth remains very robust. The order book looks strong — extremely strong for <<inaudible>> microcatheters, building on the HPC acquisition made several years back. Catheter extrusions also keeps performing well. Demand is solid, and I believe conditions remain favorable for the OEM business; and despite OEM being dilutive to our gross margins, let me remind everyone that it is accretive to our operating margins and consequently a solid contributor to Teleflex as it expands.
Patrick Wood
analystAnd then, real quick, regarding that second item. On the Urology front, you obviously brought a portion of the sales team back so some training could happen. First, how's that going? What's been the internal reaction? And second, what kind of disruption does this cause? What's the typical duration for that sort of training? I realize this is somewhat open-ended, but I'm just curious.
Liam Kelly
executiveNo, Patrick, that's a reasonable question. The training, I'd say, is progressing nicely; we're proctoring our sales reps; as the first quarter closed, roughly 40% of those who need training in this phase have gotten it. So completion will happen at the end of Q2. Then during the rest of the year, we'll follow a systematic approach for onboarding more reps and getting them fully bagged. Our expectation is that the organization will be fully integrated and essentially all the training will be finished by the end of this year, with Palette integrated as well. The positive part is that there's been 0 impact. Although UroLift did see some impact, Palette experienced 0 impact. And Palette, once more, 6 months into our ownership, is doing very well.
Jayson Bedford
analystPerhaps to kick things off for Tom. Gross margin in Q1 came in higher than the guidance you gave for the entire year. Revenue is going to rise above Q1 levels. So what is it that weighs on gross margin across the remaining 3 quarters?
Tom Powell
executiveHonestly, I can't point to anything that is specifically weighing on us across the coming quarters beyond what already showed up in Q1, where we have inflationary pressure. There's also some FX, though we anticipate FX getting better as we move through the quarters; so clearly, we got off to a very strong start this year. We put out full year guidance and we're working toward it. What I'd add is that given that strong start, we feel quite confident about hitting that guidance, and we'll keep watching how things develop and give any updates down the road when circumstances call for it.
Jayson Bedford
analystAll right, that's reasonable. Then, shifting gears, perhaps a quick separate question. Interventional had a really impressive showing against a difficult comparison, Liam. You mentioned several factors, but could you give us a bit more detail? Is this outsized share capture? Is there some new offering involved that's fueling this expansion?
Liam Kelly
executiveI'd say describing it as a new offering isn't quite right; however, clearly, MANTA keeps making inroads into the large bore segment, with truly robust double-digit expansion stemming from that device in particular — complex catheters, which represent the core of this business, meaning the guideline or trap line or Turnpike. Those keep expanding their position in the marketplace. And clearly, beyond that, our intra-aortic balloon pumps and catheters are performing very well, especially internationally. So taking everything together, I believe procedure volumes worldwide in the cath lab have returned to pre-pandemic levels. We're capturing some upside from that, yet also deepening our presence in accounts by offering a portfolio of products that complements MANTA, and with Wattson now entering the market through a limited market launch, that only serves to amplify that growth across the cath lab space.
Shagun Singh Chadha
analystLiam, at the midpoint your 2024 guidance implies roughly 4.25% growth, compared with 6.5% a year ago and your long-range plan goal at the bottom of the 6% to 7% range. I realize you flagged certain year-over-year items to keep in mind, but I'm curious about what steps up the company's growth trajectory from this point. How do you view M&A lifting your weighted average market growth? And if you could tie all of that back to what you said about utilization — it appears there's no backlog, yet demand remains healthy — that would be quite useful.
Liam Kelly
executiveNo, certainly, Shagun. Thanks so much for asking; so the midpoint of our guidance, you've got it right at the midpoint. And I'd now remind the investment community that, as we set out when — as we provided our guidance, there's roughly a 1% headwind of an inorganic nature tied to the MSA in palette. So when you take our guidance of 3.75% to 4.75%, the organic growth beneath that comes to 4.75% to 5.75%. So your entry point into the following year will be at a greater rate in terms of growth, since the MSA will have its anniversary during the fourth quarter. From a growth standpoint, I'd say the outlook for Teleflex is strong. Regarding our 6% long-range plan, we can clearly see a path to reaching it. I'd say the environment is abundant. Several portions of our business are truly doing well. We cited OEM. We cited Interventional Access. Surgical got off to a very strong start this year. Interventional Urology at 6.1%. And then by region, you observe EMEA landing at 9.7% along with double-digit growth in APAC; so I'd say the underlying growth algorithm at Teleflex remains very much intact. And as we move into — and we're 1 quarter into the second year of our LRP, and we feel fairly bullish regarding our company's outlook.
Nathan Treybeck
analystNathan Treybeck here, filling in for Larry. With the constant currency beat in Q1, could you discuss some of the factors behind the decision not to increase the full year guidance?
Liam Kelly
executiveSure. So the first thing, clearly, is that we're only one quarter in, and that needs to be factored in. Another point is that our guidance was issued in February, and March turned out to be exceptionally strong. That certainly helped. We ended up above our expectations, thanks to how March performed and some of the results we mentioned previously; also, certain OEM orders shifted from Q2 into Q1, and we adjusted for FX. So as we move through Q2, Q3 and Q4, we'll keep watching how things develop. That said, I remain quite optimistic about how we're doing. This marks our fifth consecutive quarter in which we've been positioned to exceed our internal revenue projection and deliver upside. And that upside is a solid $11 million. Again, a few million came from OEM orders that went out in Q1 instead of Q2; apart from that, the business's underlying growth is truly strong.
Analyst
analystOkay. Could you discuss what's driving Palette's growth? Is it gains in share, or is it expansion of the market? If you could just provide some detail on that.
Liam Kelly
executiveYes. Market expansion is really the main source of Palette's growth; we've kept introducing this product to our current customer base, and it's being taken up there. I mean, there is a bit of share movement, but I'd say our focus is more on the white space than on attempting to capture share from competitors in the market. The product is doing extremely well. The sales force is incredibly enthusiastic. After our 50 additional reps are trained, they will then be out selling that product in the marketplace in Q3 jewel bag. So that ought to help as well. And to grow the market even more, we have started, agreed to, and funded another study for expanded indications for the Barrigel product for Palette. We have pinpointed the sites that will run the study, and we expect to start enrollment very soon. So we're not content with a market of 330-odd million dollars. We want to grow that market further still, so we can create additional white space for us to expand into.
Matthew O'Brien
analystTom or Liam, I realize you'll tell me it's Q1 and all that, yet you just topped Q1 on the bottom line by roughly $0.15 or $0.14, while lifting only the low end by around a nickel; that means the midpoint rises by just about $0.025. What's behind that caution, particularly since inflationary pressures are letting up? And might we begin considering something like the upper portion of that range, simply given how trends have gone so far?
Tom Powell
executiveWell, let me start by saying we lifted the lower end by $0.09, though $0.05 — or rather, $0.04 — got offset by a rise in foreign exchange rates. So once more, we feel quite good regarding the first quarter's results. We've given full year guidance. That gives us greater confidence in our capacity to hit that full year guidance, and we'll keep watching the situation and update. But again, we're only just coming out of the first quarter, and it gives us a chance to observe a bit more how the year is unfolding.
Matthew O'Brien
analystAll right, that's reasonable. I was going to ask about UroLift, but I believe the better questions relate to Interventional, as Jason mentioned. Over multiple consecutive quarters now, that performance has been extremely robust. You have this emphasis on structural heart. Among med tech's quickest expanding segments, it ranks as one. Wattson is on the way. Could this segment produce growth that isn't necessarily at this magnitude, yet still substantially exceeding Teleflex's typical rates over the coming several years? And given how strongly the underlying market is performing overall, might this also be a priority area from an M&A standpoint?
Liam Kelly
executiveLet me address the final portion of what you asked first. Without question, it's an M&A priority, Matt. I've stated repeatedly that the cath lab appeals to me as a call point; at this point we possess a worldwide franchise built around that call point. And when we pursue M&A, it stands as one of our main areas of emphasis; it isn't our sole area of emphasis, though it remains a principal one. As for whether that growth can be sustained, I believe the Interventional portfolio we hold — with MANTA included and Wattson arriving — plus Ringer is on its way; Triumph should be introduced at some point during 2025. So an entire suite of products is heading toward this call point. And we've committed substantial resources to the R&D organization in that space to make certain that suite of products keeps flowing. So based on that foundation, I believe it's more than able to sustain growth well above Teleflex's average and serve as a growth engine for Teleflex across a multiyear stretch, though it has resulted from investment. This ranks among the areas where we've put money behind it, and our acquisition of MANTA several years back is yielding excellent results as we make inroads into that large bore closure market.
Anthony Petrone
analystI hope things are going great for everybody, and congratulations on a solid 1Q. Perhaps two questions. First, I was actually zeroing in on the Americas. It's a bit of a surprise, just from a regional standpoint, to see the Americas down slightly. And when you connect that to a few of the divisions — Vascular did quite well, OEM clearly beat expectations, and even Interventional Urology came in a bit above what we had modeled. So where exactly in the U.S. did things slip? Was it difficult comparisons? Or was it some other inventory stocking pattern in the U.S.? And I've got 1 follow-up.
Liam Kelly
executiveYes, Anthony, thank you. I hope you're doing well too. Appreciate the question. When it comes to the Americas, the largest effect there, Anthony, came from the MSA. As you may remember, the entire MSA was recorded in the Americas. So if you removed the MSA from the picture, growth for the Americas would have come in at roughly 3.5%, had you excluded the MSA. The underlying — there are a few underlying factors I'd like to highlight for the Americas as the year progresses: the Endurance recall had the biggest effect — that's within vascular, and it primarily hit the Americas. So by the time you move through Q2 and enter Q3, you'll have lapped that; and then looking at Q4, we'll also lap the MSA. So the Americas will show a improving trend as the year goes on. But do keep in mind, Anthony, that the MSA is entirely recorded in the Americas and it's entirely coming out of the Americas on a year-over-year basis, and that's really what's weighing on that number; and you had a follow-up, Anthony.
Anthony Petrone
analystYes. A quick follow-up here would be to take a high-level look back at the M&A approach at Teleflex — the company has been busy over the years and has completed a number of different deals. I recall the era of distributor tuck-ins. There were some R&D plays, though those weren't as common as the kind of here-and-now, revenue-generating, growth-accretive transactions; and naturally, the EBITDA level sits higher today. So maybe just to revisit the strategy — what gets the most priority, and what deal sizes are you considering currently?
Liam Kelly
executiveSo for Teleflex, I'd say our real focus is tuck-ins along with scale transactions; we've completed some late-stage technologies, and we've made some investments — early-stage investments into companies, and that will continue. Anthony, we possess the single most important ingredient required for M&A, and that's firepower. As Tom mentioned during his prepared remarks, our leverage stands at 1.7x. That gives us plenty of firepower. Right now, we're pursuing a great many assets. I'll tell you, and they do fall within the range extending from a tuck-in with revenue of, let's say, tens of millions up to scale transactions in the hundreds of millions. We remain mindful of dilution, particularly in this year, when the MSA going away is dilutive, you have Palette coming in as dilutive, and underlying earnings growth lands in that 8% to 10% band, as Tom laid out in his remarks, so — but I believe investors want to see that. So we're keeping that in mind. Anthony, we are disciplined, and disciplined is what we'll stay. I think lastly, multiples appear to have softened somewhat — at minimum, a portion of the high-growth assets on the public markets aren't carrying the value they did 12 months ago. And clearly, that factors into the seller's psyche too; and clearly, as a buyer, you're able to point to truly great companies on the public markets, superb companies, yet they aren't carrying the value they held 12 or 18 months ago, and that ought to be reflected in private companies too; so a healthy environment, plenty of assets, and a very, very disciplined Teleflex.
Mike Polark
analystAbout the CLEAR trial that's being presented at AUA this weekend, UroLift against Rezum — I'm interested in that. What should we reasonably anticipate there? Do you expect any effect in the field once those results come out?
Liam Kelly
executiveMike. Well, plenty of data from us is arriving at the AUA. There are 5 separate papers being presented, plus quite a few additional studies. One specific one comes from the European group, dealing with early intervention using minimally invasive therapies, and that beats keeping people on pharma by a wide margin. As for the particular trial you mentioned, its main emphasis is on faster symptom relief and better quality of life after treatment, pitting UroLift against Rezum, with results that could help health care providers and patients gain a clearer picture of what the postoperative experience is like for the patient using the product. There's also what I believe is a study on retreatment rates, and I'm genuinely eager to hear that one. I'll be at the conference in person. Beyond that, a real-world study exists on complications across all BPH treatments, and I expect that will be quite illuminating too. So we have a complete suite of podium presence at the AUA; and certainly, any of these head-to-head efforts — whether UroLift against Rezum, against other technologies, or against drugs — will prove useful for the sales force.
Mike Polark
analystThanks for that, Liam. I'd like to ask a follow-up about Urology and those figures too. I simply want to confirm I've got the right read on how things went this quarter and what's expected across the year. So running the calculation, at UroLift net of pull, I get something like a decline in the high teens compared to last year; and based on the full-year guidance, I figure UroLift is maybe down 10%; so what I'd like to clarify: First, for Q1, is my math right? You mentioned it matched your internal plan, and I just want to confirm that all checks out; and second, what's the trajectory that gets UroLift improving as the year goes on? It sounds like having the sales force past retraining and back in the field, with double bag, likely contributes. But whatever else you can share about why that product line should start climbing again for the remainder of the year would be useful.
Liam Kelly
executiveYes, of course, Mike; this has come up on earlier calls, we aren't going to — our approach is to report on total Interventional Urology, in line with all our global product categories and businesses, and product level revenue details for individual business lines or product categories inside those won't be provided. There are 4 reportable segments and we had 6 product segments. That gives you 10 ways to slice and dice Teleflex; but with that said, let me offer a bit of color. I'll take the full year first, then return to the quarter. Across the full year, our expectation — and nothing in our expectation for Interventional Urology has changed. I have a great deal of confidence in delivering 7.5% growth in 2024, which sat at the midpoint of our guidance. That figure includes Palette Life Sciences revenue of $66 million to $68 million, which offsets the year-over-year declines in UroLift. Now turning to the quarter, Interventional Urology grew 6.1%. Palette landed in line with what we expected and keeps performing very well. UroLift's performance likewise fell within our expectations; and as anticipated, UroLift took a hit from the declines on the office side of the service, plus from the cross training. And your read is right, Mike. As the year progresses, for those 50, that cross-training will be more or less finished once Q3 arrives and after; so we feel good about 7.5% on a full year basis for the Interventional Urology business unit.
Craig Bijou
analystCraig, I realize you won't dive into the details for '25, but when people look at '25, their expectations for margin expansion have been reduced. So perhaps you could discuss a few of the ways margins might be improved in '25 and how those are shaping up, without giving exact figures, just speaking about where you might see some gains.
Liam Kelly
executiveLiam, I'd say it begins with the gross margin line. Looking at this year, at the midpoint, our gross margins will grow by roughly 100 basis points. Our start to the year has been quite strong. In Q1, gross margins grew 170 basis points. My late mother used to say a good start is half the battle, and our start on the gross margin line has been quite strong. Looking ahead, several catalysts exist for the gross margin line to materialize; our global supply chain team keeps running continuous improvement programs; Palette, the MSA will be finished once we reach 2025. Palette will keep ramping as we reach 2025. Those 2 factors clearly will support our gross margins. And I think positive pricing will persist in '25. So that mix plus positive pricing, continuous improvement programs. Then specifically for Palette, you'll start gaining leverage on the op margin line, where it turns accretive to op margin, and our company is very disciplined about OpEx. So I truly believe everything begins and ends with the gross margin line and we — and it will flow through to operating margin going forward. And I feel confident about our chances to keep driving both growth and operating margin leverage on a solid 6% top line growth for Teleflex and underlying 10% EPS growth, which is basically what we're delivering this year.
Craig Bijou
analystFor my follow-up, I'd like to focus on standard bariatrics and Titan. As the range of offerings in that area grows, could you take us through the expected contributions from Titan and standard bariatrics in '24 and afterward? Also, what might the recent commercial update or the launch of a new product do for growth?
Liam Kelly
executiveSure, Craig. First, on the expansion of the product line: buttress represents a major enhancement to the Titan offering. Among surgeons performing gastric sleeves, 60% rely on buttress. Strictly speaking, the Titan product doesn't require a buttress, given its seal pressure and the extremely high burst pressure it can handle. Even so, that's the option they prefer to use. So we've supplied them with exactly that, and the bariatric community has responded really positively. As for Q1, Titan performed right in line with what we had expected, which was a nice way to begin the year. My view hasn't changed — I believe it will drive growth both this year and in the years ahead. To offer a bit of context on the bigger picture for gastric sleeves, I suspect that's something investors would find interesting. During the latter six months of the year, we observed a decline of 10% to 15% in gastric sleeve procedures. What this indicates for Teleflex, I believe, is that the addressable market we are expanding within may be somewhat smaller than the $250 million plus figure we previously shared. Even so, ultimately it remains a substantial market for growth, presenting ample chances for us to drive adoption of the Titan product within the gastric sleeve segment. Pardon me, I'd like to mention one additional point, Craig. Once more, throughout the quarter, we conducted extensive proctoring and surgeon training efforts. I apologize for interrupting you, operator.
Richard Newitter
analystSam here, filling in for Rich. To start us off, regarding the second quarter, I believe the range is $760 million to $765 million, which is slightly under what the Street had. A portion of that comes from FX, and another portion stems from the OEM pull forward; but is there anything else you'd highlight for 2Q to kind of account for the gap between the Street and the guidance?
Liam Kelly
executiveNo. Those represent the two main categories, Sam. FX accounts for roughly $6 million in Q2, and additionally, there are a few million in OEM products that had initially been slated for shipment during Q2. Just keep in mind that the MSA came in a bit higher during Q2, so that's something to keep in mind; and as the year progresses, you have that MSA dynamic, plus you have the dynamic of Palette ramping up over the course of the year. So you've identified the two primary factors affecting Q2. $760 million, $765 million, 3.7%, and we're confident in our capacity to hit that.
Analyst
analystGreat. And then just regarding Palette — I realize you probably want to steer clear of this since it's product-specific, but you gave us that $66 million to $68 million figure. I'm just wondering what you'd need to see in the market or in the results for that range to move higher, and what would make you feel confident about that.
Liam Kelly
executiveYes, Sam. So the first thing I'd mention is that it got off to a really strong start. Second, there's a great deal of excitement around this product. And third, broadening the indications represents a central part of our strategy — not during this year, but in later years — as a way to keep growing it. It's a distinct use case that simply can't be served by any other spacing approach. What's resonating strongly with both radiation oncologists and urologists is how noticeable the product is, the ability to shape it, and the fact that there's no pressure to hurry its use. So let's put another 1 or 2 quarters behind us, Sam, and at that point we'll return to the investment community with our view on that $66 million to $68 million range. Still, sitting here right now, I have strong confidence in the $66 million to $68 million figure.
Kristen Stewart
analystI wanted to ask about the Vascular Access segment, which arrived somewhat below my expectations. Could you speak to how it did during the quarter and what lies ahead for the rest of the year?
Liam Kelly
executiveKristen, that's a sharp observation and a fair question. The Endurance recall hit the vascular business during Q1, and we'll lap that as we move through Q2. Once you reach Q3, you'll have an unobstructed view of Vascular. So vascular ought to show improvement as the year progresses. Another point on the Vascular business: the underlying PICC growth was quite strong, though that will also get better as we move through the year. I'd expect PICC volumes to rise as the year goes on. The underlying CVC growth is quite strong and we're very pleased with its performance. So overall, it's really the Endurance lap plus a better environment for PICCs that keeps growing as the year progresses.
Larry Keusch
executiveThanks, Polly, and I appreciate all of you for being with us on today's call. That wraps up the Teleflex Incorporated First Quarter 2024 Earnings Conference Call.
Operator
operatorThank you for joining us. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.